Total Long Term Debt (Quarterly) Chart

View Total Long Term Debt (Quarterly) for IONS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Total Long Term Debt (Quarterly) Chart
Start Trial

Historical Total Long Term Debt (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
June 30, 2026 2.189B
March 31, 2026 2.610B
December 31, 2025 2.605B
September 30, 2025 2.049B
June 30, 2025 1.975B
March 31, 2025 1.958B
December 31, 2024 1.950B
September 30, 2024 1.985B
June 30, 2024 1.977B
March 31, 2024 1.969B
December 31, 2023 1.959B
September 30, 2023 1.975B
June 30, 2023 2.009B
March 31, 2023 1.875B
December 31, 2022 1.362B
September 30, 2022 1.254B
June 30, 2022 1.253B
March 31, 2022 1.252B
December 31, 2021 1.248B
September 30, 2021 1.245B
June 30, 2021 1.249B
March 31, 2021 878.60M
December 31, 2020 630.83M
September 30, 2020 820.66M
June 30, 2020 809.20M
Date Value
March 31, 2020 798.78M
December 31, 2019 785.53M
September 30, 2019 674.33M
June 30, 2019 675.30M
March 31, 2019 666.08M
December 31, 2018 646.72M
September 30, 2018 638.62M
June 30, 2018 625.84M
March 31, 2018 614.42M
December 31, 2017 607.48M
September 30, 2017 597.65M
June 30, 2017 604.13M
March 31, 2017 595.91M
December 31, 2016 589.10M
September 30, 2016 495.27M
June 30, 2016 484.99M
March 31, 2016 478.90M
December 31, 2015 481.16M
September 30, 2015 472.07M
June 30, 2015 466.90M
March 31, 2015 462.27M
December 31, 2014 457.78M
September 30, 2014 234.76M
June 30, 2014 233.92M
March 31, 2014 233.23M

Total Long Term Debt Definition

Represents a company's total debt maturing for more than 12 months of the reporting period.

Read full definition.

Total Long Term Debt (Quarterly) Range, Past 5 Years

View Total Long Term Debt (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Total Long Term Debt (Quarterly) Benchmarks

View Total Long Term Debt (Quarterly) Benchmarks
Start Trial
Alnylam Pharmaceuticals, Inc. 2.942B
Biogen, Inc. 8.355B
BridgeBio Pharma, Inc. 3.370B
Vertex Pharmaceuticals, Inc. 1.978B
Arrowhead Pharmaceuticals, Inc. 1.371B